Selected research
Industry Research
Vasculitis Drug Industry Research Report 2026
Market perspective
The global Vasculitis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vasculitis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vasculitis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vasculitis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vasculitis Drug include Shanghaihuangxiang Lantian Pharmaceutical, Merck, Huzhou Konch Pharmaceutical, Hubei Biocause Pharmaceutical, Hainan Pharmaceutical Factory, Bayer, Sino-US Zibo Xinhua-Perrigo Pharmaceutical, Farmalider and CSPC Ouyi Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vasculitis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vasculitis Drug Market by Company
Shanghaihuangxiang Lantian Pharmaceutical
Merck
Huzhou Konch Pharmaceutical
Hubei Biocause Pharmaceutical
Hainan Pharmaceutical Factory
Bayer
Sino-US Zibo Xinhua-Perrigo Pharmaceutical
Farmalider
CSPC Ouyi Pharmaceutical
Vasculitis Drug Segment by Type
CCX-168
Blisibimod
Gevokizumab
Rituximab Biosimilar
Others
Vasculitis Drug Segment by Application
Thrombotic Vasculitis
Granulomatous Vasculitis
Lymphocytic Vasculitis
Polyarteritis Nodosa
Others
Vasculitis Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasculitis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vasculitis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasculitis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vasculitis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vasculitis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vasculitis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CCX-168
- Blisibimod
- Gevokizumab
- Rituximab Biosimilar
- Others
Applications
- Thrombotic Vasculitis
- Granulomatous Vasculitis
- Lymphocytic Vasculitis
- Polyarteritis Nodosa
- Others
Companies covered
- Shanghaihuangxiang Lantian Pharmaceutical
- Merck
- Huzhou Konch Pharmaceutical
- Hubei Biocause Pharmaceutical
- Hainan Pharmaceutical Factory
- Bayer
- Sino-US Zibo Xinhua-Perrigo Pharmaceutical
- Farmalider
- CSPC Ouyi Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vasculitis Drug Market Size (2021-2032)
- 2.2.2 Global Vasculitis Drug Sales (2021-2032)
- 2.2.3 Global Vasculitis Drug Market Average Price (2021-2032)
- 2.3 Vasculitis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CCX-168
- 2.3.3 Blisibimod
- 2.3.4 Gevokizumab
- 2.3.5 Rituximab Biosimilar
- 2.3.6 Others
- 2.4 Vasculitis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Thrombotic Vasculitis
- 2.4.3 Granulomatous Vasculitis
- 2.4.4 Lymphocytic Vasculitis
- 2.4.5 Polyarteritis Nodosa
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vasculitis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vasculitis Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Vasculitis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Vasculitis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Vasculitis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vasculitis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vasculitis Drug, Product Type & Application
- 3.8 Global Manufacturers of Vasculitis Drug, Established Date
- 3.9 Global Vasculitis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Shanghaihuangxiang Lantian Pharmaceutical
- 4.1.1 Shanghaihuangxiang Lantian Pharmaceutical Company Information
- 4.1.2 Shanghaihuangxiang Lantian Pharmaceutical Business Overview
- 4.1.3 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Shanghaihuangxiang Lantian Pharmaceutical Vasculitis Drug Product Portfolio
- 4.1.5 Shanghaihuangxiang Lantian Pharmaceutical Recent Developments
- 4.2 Merck
- 4.2.1 Merck Company Information
- 4.2.2 Merck Business Overview
- 4.2.3 Merck Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck Vasculitis Drug Product Portfolio
- 4.2.5 Merck Recent Developments
- 4.3 Huzhou Konch Pharmaceutical
- 4.3.1 Huzhou Konch Pharmaceutical Company Information
- 4.3.2 Huzhou Konch Pharmaceutical Business Overview
- 4.3.3 Huzhou Konch Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Huzhou Konch Pharmaceutical Vasculitis Drug Product Portfolio
- 4.3.5 Huzhou Konch Pharmaceutical Recent Developments
- 4.4 Hubei Biocause Pharmaceutical
- 4.4.1 Hubei Biocause Pharmaceutical Company Information
- 4.4.2 Hubei Biocause Pharmaceutical Business Overview
- 4.4.3 Hubei Biocause Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hubei Biocause Pharmaceutical Vasculitis Drug Product Portfolio
- 4.4.5 Hubei Biocause Pharmaceutical Recent Developments
- 4.5 Hainan Pharmaceutical Factory
- 4.5.1 Hainan Pharmaceutical Factory Company Information
- 4.5.2 Hainan Pharmaceutical Factory Business Overview
- 4.5.3 Hainan Pharmaceutical Factory Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hainan Pharmaceutical Factory Vasculitis Drug Product Portfolio
- 4.5.5 Hainan Pharmaceutical Factory Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Vasculitis Drug Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 Sino-US Zibo Xinhua-Perrigo Pharmaceutical
- 4.7.1 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Company Information
- 4.7.2 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Business Overview
- 4.7.3 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Vasculitis Drug Product Portfolio
- 4.7.5 Sino-US Zibo Xinhua-Perrigo Pharmaceutical Recent Developments
- 4.8 Farmalider
- 4.8.1 Farmalider Company Information
- 4.8.2 Farmalider Business Overview
- 4.8.3 Farmalider Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Farmalider Vasculitis Drug Product Portfolio
- 4.8.5 Farmalider Recent Developments
- 4.9 CSPC Ouyi Pharmaceutical
- 4.9.1 CSPC Ouyi Pharmaceutical Company Information
- 4.9.2 CSPC Ouyi Pharmaceutical Business Overview
- 4.9.3 CSPC Ouyi Pharmaceutical Vasculitis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSPC Ouyi Pharmaceutical Vasculitis Drug Product Portfolio
- 4.9.5 CSPC Ouyi Pharmaceutical Recent Developments
5 Global Vasculitis Drug Market Scenario by Region
- 5.1 Global Vasculitis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vasculitis Drug Sales by Region: 2021-2032
- 5.2.1 Global Vasculitis Drug Sales by Region: 2021-2026
- 5.2.2 Global Vasculitis Drug Sales by Region: 2027-2032
- 5.3 Global Vasculitis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Vasculitis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Vasculitis Drug Revenue by Region: 2027-2032
- 5.4 North America Vasculitis Drug Market Facts & Figures by Country
- 5.4.1 North America Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vasculitis Drug Sales by Country (2021-2032)
- 5.4.3 North America Vasculitis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Vasculitis Drug Market Facts & Figures by Country
- 5.5.1 Europe Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vasculitis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Vasculitis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Vasculitis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vasculitis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vasculitis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vasculitis Drug Market Facts & Figures by Country
- 5.7.1 South America Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vasculitis Drug Sales by Country (2021-2032)
- 5.7.3 South America Vasculitis Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Vasculitis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vasculitis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vasculitis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vasculitis Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Vasculitis Drug Sales by Type (2021-2032)
- 6.1.1 Global Vasculitis Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Vasculitis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Vasculitis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Vasculitis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vasculitis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Vasculitis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vasculitis Drug Sales by Application (2021-2032)
- 7.1.1 Global Vasculitis Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Vasculitis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Vasculitis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Vasculitis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vasculitis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Vasculitis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vasculitis Drug Value Chain Analysis
- 8.1.1 Vasculitis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vasculitis Drug Production Mode & Process
- 8.2 Vasculitis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vasculitis Drug Distributors
- 8.2.3 Vasculitis Drug Customers
9 Global Vasculitis Drug Analyzing Market Dynamics
- 9.1 Vasculitis Drug Industry Trends
- 9.2 Vasculitis Drug Industry Drivers
- 9.3 Vasculitis Drug Industry Opportunities and Challenges
- 9.4 Vasculitis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst